Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer

An independent prognostic factor of survival

D. Nitti, C. Belluco, M. C. Montesco, R. Bertorelle, P. P. Da Pian, A. Fassina, V. Ninfo, L. Chieco-Bianchi, M. Lise

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

An association has been reported between nuclear p53 protein expression in tumour cells and a poor outcome in patients with colorectal cancer (CRC). In this study we investigated the prognostic significance of nuclear p53 protein expression in CRC liver metastases after curative hepatic resection. The study population consisted of 69 consecutive patients who underwent curative hepatic resection for metastases from CRC at our Institution between February 1987 and October 1993. Immunohistochemical expression of p53 protein was evaluated in formalin-fixed paraffin-embedded sections of CRC liver metastases using the monoclonal antibodies (MAbs) D01 and Pab 1801. The Cox proportional hazards model was used in forward stepwise regression to assess the relative influence of different prognostic factors. Forty-four (63.8%) CRC liver metastases were p53-positive. Kaplan-Meier survival curves demonstrated that patients with p53-positive metastases had a median survival of 27 months versus 93 months for patients with p53-negative metastases (P <0.01). The 3 and 5 year survival rates were 31.5 and 21.0% in patients with p53-positive metastases and 71.8 and 53.1% in patients with p53-negative metastases. At multivariate analysis p53 protein status was the single best predictor of survival (P = 0.0079); the odds ratio of death among patients with p53-positive tumours was 2.53. Nuclear p53 protein expression in hepatic metastases from CRC is an independent prognostic factor of survival following liver resection. These findings may be of clinical importance in the selection of patients more likely to benefit from liver resection and could be used as criteria for stratification in trials on adjuvant therapy.

Original languageEnglish
Pages (from-to)851-855
Number of pages5
JournalEuropean Journal of Cancer
Volume34
Issue number6
DOIs
Publication statusPublished - May 1998

Fingerprint

Nuclear Proteins
Colorectal Neoplasms
Neoplasm Metastasis
Survival
Liver
Liver Neoplasms
Kaplan-Meier Estimate
Proportional Hazards Models
Paraffin
Patient Selection
Formaldehyde
Neoplasms
Proteins
Multivariate Analysis
Survival Rate
Odds Ratio
Monoclonal Antibodies

Keywords

  • Colorectal cancer
  • Liver metastases
  • p53 protein
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer : An independent prognostic factor of survival. / Nitti, D.; Belluco, C.; Montesco, M. C.; Bertorelle, R.; Da Pian, P. P.; Fassina, A.; Ninfo, V.; Chieco-Bianchi, L.; Lise, M.

In: European Journal of Cancer, Vol. 34, No. 6, 05.1998, p. 851-855.

Research output: Contribution to journalArticle

@article{87fccd0180da48759ba1e4714822b04f,
title = "Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: An independent prognostic factor of survival",
abstract = "An association has been reported between nuclear p53 protein expression in tumour cells and a poor outcome in patients with colorectal cancer (CRC). In this study we investigated the prognostic significance of nuclear p53 protein expression in CRC liver metastases after curative hepatic resection. The study population consisted of 69 consecutive patients who underwent curative hepatic resection for metastases from CRC at our Institution between February 1987 and October 1993. Immunohistochemical expression of p53 protein was evaluated in formalin-fixed paraffin-embedded sections of CRC liver metastases using the monoclonal antibodies (MAbs) D01 and Pab 1801. The Cox proportional hazards model was used in forward stepwise regression to assess the relative influence of different prognostic factors. Forty-four (63.8{\%}) CRC liver metastases were p53-positive. Kaplan-Meier survival curves demonstrated that patients with p53-positive metastases had a median survival of 27 months versus 93 months for patients with p53-negative metastases (P <0.01). The 3 and 5 year survival rates were 31.5 and 21.0{\%} in patients with p53-positive metastases and 71.8 and 53.1{\%} in patients with p53-negative metastases. At multivariate analysis p53 protein status was the single best predictor of survival (P = 0.0079); the odds ratio of death among patients with p53-positive tumours was 2.53. Nuclear p53 protein expression in hepatic metastases from CRC is an independent prognostic factor of survival following liver resection. These findings may be of clinical importance in the selection of patients more likely to benefit from liver resection and could be used as criteria for stratification in trials on adjuvant therapy.",
keywords = "Colorectal cancer, Liver metastases, p53 protein, Prognosis",
author = "D. Nitti and C. Belluco and Montesco, {M. C.} and R. Bertorelle and {Da Pian}, {P. P.} and A. Fassina and V. Ninfo and L. Chieco-Bianchi and M. Lise",
year = "1998",
month = "5",
doi = "10.1016/S0959-8049(97)10165-4",
language = "English",
volume = "34",
pages = "851--855",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer

T2 - An independent prognostic factor of survival

AU - Nitti, D.

AU - Belluco, C.

AU - Montesco, M. C.

AU - Bertorelle, R.

AU - Da Pian, P. P.

AU - Fassina, A.

AU - Ninfo, V.

AU - Chieco-Bianchi, L.

AU - Lise, M.

PY - 1998/5

Y1 - 1998/5

N2 - An association has been reported between nuclear p53 protein expression in tumour cells and a poor outcome in patients with colorectal cancer (CRC). In this study we investigated the prognostic significance of nuclear p53 protein expression in CRC liver metastases after curative hepatic resection. The study population consisted of 69 consecutive patients who underwent curative hepatic resection for metastases from CRC at our Institution between February 1987 and October 1993. Immunohistochemical expression of p53 protein was evaluated in formalin-fixed paraffin-embedded sections of CRC liver metastases using the monoclonal antibodies (MAbs) D01 and Pab 1801. The Cox proportional hazards model was used in forward stepwise regression to assess the relative influence of different prognostic factors. Forty-four (63.8%) CRC liver metastases were p53-positive. Kaplan-Meier survival curves demonstrated that patients with p53-positive metastases had a median survival of 27 months versus 93 months for patients with p53-negative metastases (P <0.01). The 3 and 5 year survival rates were 31.5 and 21.0% in patients with p53-positive metastases and 71.8 and 53.1% in patients with p53-negative metastases. At multivariate analysis p53 protein status was the single best predictor of survival (P = 0.0079); the odds ratio of death among patients with p53-positive tumours was 2.53. Nuclear p53 protein expression in hepatic metastases from CRC is an independent prognostic factor of survival following liver resection. These findings may be of clinical importance in the selection of patients more likely to benefit from liver resection and could be used as criteria for stratification in trials on adjuvant therapy.

AB - An association has been reported between nuclear p53 protein expression in tumour cells and a poor outcome in patients with colorectal cancer (CRC). In this study we investigated the prognostic significance of nuclear p53 protein expression in CRC liver metastases after curative hepatic resection. The study population consisted of 69 consecutive patients who underwent curative hepatic resection for metastases from CRC at our Institution between February 1987 and October 1993. Immunohistochemical expression of p53 protein was evaluated in formalin-fixed paraffin-embedded sections of CRC liver metastases using the monoclonal antibodies (MAbs) D01 and Pab 1801. The Cox proportional hazards model was used in forward stepwise regression to assess the relative influence of different prognostic factors. Forty-four (63.8%) CRC liver metastases were p53-positive. Kaplan-Meier survival curves demonstrated that patients with p53-positive metastases had a median survival of 27 months versus 93 months for patients with p53-negative metastases (P <0.01). The 3 and 5 year survival rates were 31.5 and 21.0% in patients with p53-positive metastases and 71.8 and 53.1% in patients with p53-negative metastases. At multivariate analysis p53 protein status was the single best predictor of survival (P = 0.0079); the odds ratio of death among patients with p53-positive tumours was 2.53. Nuclear p53 protein expression in hepatic metastases from CRC is an independent prognostic factor of survival following liver resection. These findings may be of clinical importance in the selection of patients more likely to benefit from liver resection and could be used as criteria for stratification in trials on adjuvant therapy.

KW - Colorectal cancer

KW - Liver metastases

KW - p53 protein

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0032077389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032077389&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(97)10165-4

DO - 10.1016/S0959-8049(97)10165-4

M3 - Article

VL - 34

SP - 851

EP - 855

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -